Endologix, Inc. (ELGX)
Lifshitz & Miller announces investigation on behalf of ELGX investors. The investigation concerns whether ELGX violated federal securities laws by issuing false and misleading statements concerning the Nellix investigational device exemption clinical trial.
If you are a ELGX investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at email@example.com.